Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A 2025 meta-analysis looked at five studies on GLP-1s for people with eating disorders and found that people with BED taking a GLP-1 showed a reduction in binge eating symptoms and lost significantly more weight compared to control groups
Results Timeline Chart Understanding when to expect results helps set realistic expectations and prevents premature protocol abandonment
*Disclaimer: Major Players sorted in no particular order Recent Industry Developments March 2023: Novo Nordisk announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as an add-on to a stable dose of 1-3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification
Rt mong nhn c s ng h v tn nhim lu di ca qu khch hng
